PharmaEssentia breaks ground on Hsinchu plant
PharmaEssentia Corp (藥華醫藥), which provides drugs for a rare type of blood cancer, broke ground for a new factory in Hsinchu, which is scheduled to be completed in 2025. The plant is expected to boost the company’s annual production value by NT$40 billion (US$1.25 billion), executives from the firm said at the groundbreaking ceremony.
The NT$5.1 billion plant comprises 50,000m2 to manufacture the polycythemia vera (PV) drug Ropeginterferon alfa-2b, also known as Ropeg. Approved by the US Food and Drug Administration in November last year, Ropeg is PharmaEassentia’s most significant product, and helped boost the firm’s revenue to NT$2.04 billion in the first nine months, six times higher than a year earlier.
“Ropeg has gained approval in Taiwan, the EU, Switzerland, Israel, South Korea and the US. Now we are targeting Japan and China as the drug’s next markets,” PharmaEssentia chairwoman Teng Ching-leou said at the ceremony. “The company is conducting a phase 3 clinical trial to determine whether Ropeg can also treat essential thrombocythemia, an uncommon disorder in which bone marrow produces too many platelets.”
The construction of the new plant in Hsinchu County’s Jhubei City is expected to be finished in the first quarter of 2025, and enter mass production later that year after testing and an inspection by the US Food and Drug Administration.
PharmaEssentia Corporation is a fully integrated global biopharmaceutical company delivering efficacious, safe and cost-effective therapeutic products for the treatment of human diseases while aiming to bring long lasting value to stakeholders. PharmaEssentia was founded in 2003 by a group of Taiwanese-American executives and high-ranking scientists from leading U.S. biotechnology and pharmaceutical companies in order to develop treatments for myeloproliferative neoplasms, hepatitis and other diseases. The company is committed to the improvement of health and quality of life for patients suffering from these diseases. The Company’s world-class cGMP biologics facility in Taichung is certified by the Taiwan Food and Drug Administration (TFDA) and is designed and operated to be compliant with all U.S. FDA and EMA requirements.